

Country Demographics <sup>1, 2</sup>	
Total Population (2018) <sup>1</sup>	19,077,690
Urban Population (% of total, 2018) <sup>1</sup>	42.4%
Health expenditure per capita (\$US, 2016) <sup>1</sup>	\$29.8
Health expenditure, total (% of GDP, 2016) <sup>1</sup>	3.8%
Total births (2013) <sup>2</sup>	723,000
Surviving Infants (2013) <sup>2</sup>	661,000
Life expectancy at birth (years, 2017) <sup>1</sup>	58.5 years
Number of districts (2013) <sup>2</sup>	60


HBsAg Prevalence <sup>3</sup>	
Pre-vaccine HBsAG+ (%)	11.5%

Liver Cancer as Cause of Cancer Death (in Men) <sup>4</sup>	
Year: 2018	Ranking: 2

2018 Country Comparison in African Region (47 Countries) <sup>5</sup>				
	Mali	Number of countries with reported coverage	Highest reported coverage in AFR	Lowest reported coverage in AFR
HepB3 <sup>5</sup>	71%	47	99% (Cabo Verde, Seychelles)	25% (Equatorial Guinea)
HepB BD <sup>5</sup>	NR	4	99% (Algeria)	63% (Senegal)

Hepatitis B Immunization Coverage																			
	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018
HepB3	NR	NR	NR	79%	73%	83%	90%	74%	74%	71%	72%	66%	65%	64%	66%	67%	69%	70%	71%
HepB BD	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
BCG	69%	75%	82%	74%	76%	83%	86%	86%	86%	84%	82%	84%	77%	70%	73%	76%	77%	81%	83%

Mali: HepB3



Abbreviations: NA= not applicable; NR= no report; HepB BD= birth dose within 24 hours; HepB3= at least 3 doses of HepB vaccine; HBsAG= HepB surface antigen. Data Compiled by Asian Liver Center at Stanford University 2019: World DataBank: World Development Indicators database<sup>1</sup>, WHO Immunization Summary: A statistical reference containing data through 2013<sup>2</sup>, WHO Public Health Significance, Targets, Strategies: HBV country profiles<sup>3</sup>, Global Cancer Observatory: Cancer Today-IARC<sup>4</sup>, WHO Vaccine-Preventable Diseases: Monitoring System. 2019 global summary WHO-UNICEF estimates<sup>5</sup>